tamoxifen and glp-1 Agonists Poised to Impact Breast Cancer Care | Targeted Oncology 2 Years of Endocrine Therapy,
Description
In order to fuel global expansion, companies are investing in developing new drugs in sustained release and oral modality, add capacity for production, enhance patient support programs, and write applications for regulatory approval of additional indications
European Journal of Neuroscience
Agents such as semaglutide and tirzepatide have demonstrated especially notable efficacy in this regard, further reinforcing the concept that targeted weight management can meaningfully influence cardiovascular outcomes
10.1210/en.2013-2106 31 KimH.WrannC
